Literature DB >> 21646468

Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation.

Irina A Oussenko1, James F Holland, E Premkumar Reddy, Takao Ohnuma.   

Abstract

The benzyl styryl sulfone, ON 01910.Na, is a novel anticancer agent that inhibits mitotic progression and induces apoptosis in most cancer cell lines. We examined the effect of ON 01910.Na on DNA damage-signaling molecules upstream of Cdc25C (Chk1, Chk2, and H2AX), as well as on Ran GTPase-activating protein 1 conjugated to small ubiquitin-related modifier 1 (RanGAP1·SUMO1), a mitosis coordinator. Prostate cancer, lymphoma, and leukemic cells were incubated with the drug for 4, 16, or 24 hours. Cell lysates were resolved on SDS-PAGE and analyzed by Western blot. Camptothecin and doxorubicin treatment caused activation/phosphorylation of DNA damage-responsive molecules by 4 hours, whereas ON 01910.Na did not do so. ON 01910.Na caused hyperphosphorylation of RanGAP1·SUMO1 within 4 hours that was sustained for more than 24 hours. Mild phosphorylation of Chk2 was observed only after 24-hour exposure, indicating that DNA damage response was not an initial effect of ON 01910.Na. MOLT-3 cells, synchronized by double-thymidine block, when released into a medium containing ON 01910.Na, accumulated mitotic cell number with a peak from 10 to 14 hours and remained near plateau for 20 hours, which corresponded with the time of RanGAP phosphorylation. ON 01910.Na had minimal effects on tubulin polymerization. These findings imply that ON 01910.Na neither induces DNA damage directly nor acts as a tubulin toxin. Its biological activity appears to rely on prolonged phosphorylation/hyperphosphorylation of RanGAP1·SUMO1. M-phase arrest and the consequent induction of apoptosis that follows could possibly be attributed to it. ON 01910.Na may act as an inhibitor of a RanGAP1·SUMO1 phosphatase or a stimulant of a new kinase. RanGAP1·SUMO1 appears to be a new target pathway for cancer chemotherapy. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21646468     DOI: 10.1158/0008-5472.CAN-10-1603

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

Review 1.  Novel drugs for older patients with acute myeloid leukemia.

Authors:  G Montalban-Bravo; G Garcia-Manero
Journal:  Leukemia       Date:  2014-08-21       Impact factor: 11.528

2.  Prevention of Doxorubicin cardiopathic changes by a benzyl styryl sulfone in mice.

Authors:  Min Lu; Salim Merali; Ronald Gordon; Jiandong Jiang; Yan Li; John Mandeli; Xunbao Duan; John Fallon; James F Holland
Journal:  Genes Cancer       Date:  2011-10

3.  ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.

Authors:  Colby M Chapman; Xiameng Sun; Mark Roschewski; Georg Aue; Mohamed Farooqui; Lawrence Stennett; Federica Gibellini; Diane Arthur; Patricia Pérez-Galán; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2012-02-20       Impact factor: 12.531

4.  Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies.

Authors:  M Roschewski; M Farooqui; G Aue; F Wilhelm; A Wiestner
Journal:  Leukemia       Date:  2013-03-14       Impact factor: 11.528

Review 5.  Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.

Authors:  Alice C Fan; Jennifer J O'Rourke; Dave R Praharaj; Dean W Felsher
Journal:  Expert Opin Investig Drugs       Date:  2013-08-12       Impact factor: 6.206

6.  Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.

Authors:  Takao Ohnuma; Deborah Lehrer; Chen Ren; Sool Yeon Cho; Manoj Maniar; Lewis Silverman; Max Sung; Herbert F Gretz; Vladimir Benisovich; Shyamala Navada; Eugene Akahoho; Eric Wilck; David R Taft; John Roboz; Francois Wilhelm; James F Holland
Journal:  Am J Cancer Res       Date:  2013-06-20       Impact factor: 6.166

7.  Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

Authors:  Rami S Komrokji; Azra Raza; Jeffrey E Lancet; Chen Ren; David Taft; Manoj Maniar; Francois Wilhelm; Alan F List
Journal:  Br J Haematol       Date:  2013-06-21       Impact factor: 6.998

8.  A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.

Authors:  K Mross; C Dittrich; W E Aulitzky; D Strumberg; J Schutte; R M Schmid; S Hollerbach; M Merger; G Munzert; F Fleischer; M E Scheulen
Journal:  Br J Cancer       Date:  2012-06-14       Impact factor: 7.640

9.  The novel tubulin polymerization inhibitor MHPT exhibits selective anti-tumor activity against rhabdomyosarcoma in vitro and in vivo.

Authors:  Yan Mu; Yin Liu; Liwen Li; Cong Tian; Hongyu Zhou; Qiu Zhang; Bing Yan
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

10.  Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma.

Authors:  Kung-Chao Chang; Wei-Chao Chang; Yao Chang; Liang-Yi Hung; Chien-Hsien Lai; Yu-Min Yeh; Yu-Wei Chou; Chung-Hsuan Chen
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.